Eczema future or investigational therapies: Difference between revisions

Jump to navigation Jump to search
 
(2 intermediate revisions by the same user not shown)
Line 4: Line 4:


==Overview==
==Overview==
More emphasis on [[genetic studies]] will be given in the future to unfold the remaining majority of unexplained [[heritability]] in [[eczema]]. However, the challenge still lies in the economical and computational requirements. <ref name="pmid22071473">{{cite journal| author=Brown SJ, Kroboth K, Sandilands A, Campbell LE, Pohler E, Kezic S | display-authors=etal| title=Intragenic copy number variation within filaggrin contributes to the risk of atopic dermatitis with a dose-dependent effect. | journal=J Invest Dermatol | year= 2012 | volume= 132 | issue= 1 | pages= 98-104 | pmid=22071473 | doi=10.1038/jid.2011.342 | pmc=3236450 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22071473  }} </ref>
Future trends will focus more on [[genetic studies]] in [[eczema]]. <ref name="pmid22071473">{{cite journal| author=Brown SJ, Kroboth K, Sandilands A, Campbell LE, Pohler E, Kezic S | display-authors=etal| title=Intragenic copy number variation within filaggrin contributes to the risk of atopic dermatitis with a dose-dependent effect. | journal=J Invest Dermatol | year= 2012 | volume= 132 | issue= 1 | pages= 98-104 | pmid=22071473 | doi=10.1038/jid.2011.342 | pmc=3236450 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22071473  }} </ref>


==Eczema Future or Investigational Therapies==
==Eczema Future or Investigational Therapies==
*More emphasis on [[genetic studies]] will be given in the future to unfold the remaining majority of unexplained [[heritability]] in [[eczema]]. However, the challenge still lies in the economical and computational requirements.  
* Future trends will focus more on [[genetic studies]] in [[eczema]].  
* These [[genetic discoveries]] can be applied to the development of new [[drugs]] that can target the [[molecular]] and [[physiological]] [[causes]] of the [[disease]], making an era of "personalized [[medicine]]". <ref name="pmid29217837">{{cite journal| author=Dugger SA, Platt A, Goldstein DB| title=Drug development in the era of precision medicine. | journal=Nat Rev Drug Discov | year= 2018 | volume= 17 | issue= 3 | pages= 183-196 | pmid=29217837 | doi=10.1038/nrd.2017.226 | pmc=6287751 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29217837  }} </ref>
* These [[genetic discoveries]] can be applied to the development of new [[drugs]] that can target the [[molecular]] and [[physiological]] [[causes]] of the [[disease]], making an era of "personalized [[medicine]]". <ref name="pmid29217837">{{cite journal| author=Dugger SA, Platt A, Goldstein DB| title=Drug development in the era of precision medicine. | journal=Nat Rev Drug Discov | year= 2018 | volume= 17 | issue= 3 | pages= 183-196 | pmid=29217837 | doi=10.1038/nrd.2017.226 | pmc=6287751 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29217837  }} </ref>
 
* [[Digitalization]] and [[artificial intelligence]] can also be applied to the [[management]] of [[eczema]]. <ref name="pmid33205485">{{cite journal| author=Wollenberg A, Christen-Zäch S, Taieb A, Paul C, Thyssen JP, de Bruin-Weller M | display-authors=etal| title=ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. | journal=J Eur Acad Dermatol Venereol | year= 2020 | volume= 34 | issue= 12 | pages= 2717-2744 | pmid=33205485 | doi=10.1111/jdv.16892 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=33205485  }} </ref>


==References==
==References==

Latest revision as of 00:12, 26 May 2022

Eczema Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Eczema from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Social Impact

Future or Investigational Therapies

Case Studies

Case #1

Eczema On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Eczema

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Eczema

CDC on Eczema

Eczema in the news

Blogs on Eczema

Directions to Hospitals Treating Eczema

Risk calculators and risk factors for Eczema

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Edzel Lorraine Co, D.M.D., M.D.

Overview

Future trends will focus more on genetic studies in eczema. [1]

Eczema Future or Investigational Therapies

References

  1. Brown SJ, Kroboth K, Sandilands A, Campbell LE, Pohler E, Kezic S; et al. (2012). "Intragenic copy number variation within filaggrin contributes to the risk of atopic dermatitis with a dose-dependent effect". J Invest Dermatol. 132 (1): 98–104. doi:10.1038/jid.2011.342. PMC 3236450. PMID 22071473.
  2. Dugger SA, Platt A, Goldstein DB (2018). "Drug development in the era of precision medicine". Nat Rev Drug Discov. 17 (3): 183–196. doi:10.1038/nrd.2017.226. PMC 6287751. PMID 29217837.
  3. Wollenberg A, Christen-Zäch S, Taieb A, Paul C, Thyssen JP, de Bruin-Weller M; et al. (2020). "ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children". J Eur Acad Dermatol Venereol. 34 (12): 2717–2744. doi:10.1111/jdv.16892. PMID 33205485 Check |pmid= value (help).